The Food and Drug Administration granted expedited approval on Wednesday to Eli Lilly’s new weight-loss pill, a medication used to treat obesity and other weight-related conditions. Orforglipron is a ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Food and Drug Administration has approved Foundayo, Eli Lilly’s new GLP-1 pill to treat ...

The U.S. Food and Drug Administration on Wednesday gave its approval to Eli Lilly’s GLP-1 weight loss pill. The daily pill, called Foundayo, is the second oral GLP-1 product to reach the market over ...

The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for ...

April 1 (UPI) --The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss, making it the second company to offer a non-injectable version of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Eli Lilly is building an insurmountable lead in GLP-1 drugs through superior clinical efficacy of tirzepatide, direct-to-employer distribution that bypasses pharmacy benefit managers, and a ...

Mon, March 16, 2026 at 3:19 PM UTC Coupled with its rival's partnership with Hims & Hers Health (NYSE:HIMS) to sell branded versions of the injectable and oral treatments, Lilly can’t afford to rest ...

Obesity rates are down in this country. At the same time, more and more people are taking GLP-1 weight loss drugs. A coincidence? I think not. Despite that trend, a lot of employer-sponsored health ...

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, ...

Eli Lilly LLY3.78%increase; green up pointing triangle received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...